

## New records in 2021 – Strong growth set to continue

*Mutares has published a strong set of figures for Q4/FY 2021. Backed by the brisk acquisition activities group revenues of EUR 2.5bn reached a new record level in FY 2021. Group reported EBITDA more than tripled to EUR 567m, also mainly driven by the acquisitions and the related one-time gains (bargain purchase of EUR 693m). However, it should be noted, that consolidated earnings figures reflect the operating profitability of the company in a very distorted manner. Consequently, the figures on holding level are more meaningful. The holding net income in 2021 significantly improved by 52% yoy to EUR 50.7m (PAsE: 50.4m), as a result of higher consulting fees and exit gains. The announced dividend of EUR 1.50 per share represents a very attractive dividend yield of 6.6%. Mutares has indicated a well filled acquisition pipeline with an estimated revenue size of EUR 1bn and some related announcements already in Q2e. We welcome larger acquisitions and their corresponding positive P&L impact on holding level. In addition to a higher income stream this will also increase the dividend distribution potential. The results for 2021 and the prospects confirm our positive view on the shares. With a TP of EUR 30, we rate the shares a Buy.*

- For FY 2022e the company targets group revenues of at least EUR 4bn. More important, Mutares targets to increase the net income on holding level to EUR 72m to EUR 88m (PAsE: EUR 64m). The mid-point of the guidance range implies another significant increase of close to 60% yoy.
- For FY 2021, Mutares intends to pay out a dividend of EUR 1.50 per share, of which 0.50 EUR per share is to be considered as a performance dividend. Bear in mind, that Mutares had sold six investment companies in 2021.

Zafer Rüzgar

+49 69 58997 412, zafer.ruezgar@paretosec.com

*Pareto Securities AS has been paid by the issuer to produce this research report. This material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to the EU MIFID 2 directive.*

For disclosures on relevant definitions, methods, risks, potential conflicts of interests etc. and disclaimers please see [www.paretosec.com](http://www.paretosec.com). Investment Recommendations should be reviewed in conjunction with the information therein. When distributed in the US: This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to equity/debt research reports prepared for retail investors. This material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to Directive 2014/65/EU Article 24 (7)(8) and Commission Delegated Directive 2017/593.